Arcutis Biotherapeutics Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
Arcutis Biotherapeutics (ARQT) reported strong third-quarter 2026 financial results, highlighted by a 45% year-over-year increase in total net product revenue to $143.9 million. This growth was primarily driven by high demand across the ZORYVE franchise, which reached a historical high of over 300,000 prescriptions on a rolling four-week average. Following these results, management raised its full-year 2026 revenue guidance to a range of $535 million to $545 million. The company also achieved positive operating cash flow of $18.9 million for the quarter, providing a stable financial foundation to reinvest in commercial initiatives and clinical development as they aim for a sales inflection point in 2027.
Tickers: $ARQT
Topics: guidance revision net income prescription volume revenue growth